Clinical Trial Results:
Imovax® Rabies and VERORAB® Immunogenicity and Safety after One Week 2-sites Intradermal or 1-site Intramuscular Pre- Exposure Prophylaxis Regimens, Followed by a Simulated Intradermal or Intramuscular Post-Exposure Prophylaxis Regimen at One Year
Summary
|
|
EudraCT number |
2020-001223-14 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
08 Apr 2020
|
Results information
|
|
Results version number |
v1 |
This version publication date |
14 Apr 2021
|
First version publication date |
14 Apr 2021
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
VAJ00001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03700242 | ||
WHO universal trial number (UTN) |
U1111-1183-5743 | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur
|
||
Sponsor organisation address |
14, Espace Henry Vallée, Lyon, France, 69007
|
||
Public contact |
Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
|
||
Scientific contact |
Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
18 Jan 2021
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
08 Apr 2020
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate 14 days (D) after the last PrEP vaccination (Vacc.) with human diploid cell vaccine (HDCV) (Group 1 versus Group 2).
|
||
Protection of trial subjects |
Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment were also available on site in case of any immediate allergic reactions.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
26 Sep 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Philippines: 570
|
||
Worldwide total number of subjects |
570
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
165
|
||
Adolescents (12-17 years) |
91
|
||
Adults (18-64 years) |
314
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||||
Recruitment details |
The study was conducted at 2 centres in the Philippines. A total of 570 subjects were enrolled between 26 September 2018 and 19 February 2019. | ||||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||||
Screening details |
A total of 570 subjects were enrolled and randomised in the study. | ||||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||||
Period 1 title |
PrEP vaccination phase: up to 6.5 Months
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Group 1: Short HDCV IM PrEP Regimen | ||||||||||||||||||||||||||||||
Arm description |
Subjects received a single IM dose of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Human Diploid Cell Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Imovax® Rabies
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
1 millitre (mL), single IM injection on the deltoid area of the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 2: Reference HDCV IM PrEP Regimen | ||||||||||||||||||||||||||||||
Arm description |
Subjects received a single IM dose of HDCV on Day 0, Day 7, and Day 21 and were followed up to 1 year post last PrEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Human Diploid Cell Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Imovax® Rabies
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
1 mL, single IM injection on the deltoid area of the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 3: Short HDCV Intradermal (ID) PrEP regimen | ||||||||||||||||||||||||||||||
Arm description |
Subjects received two ID doses of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Human Diploid Cell Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Imovax® Rabies
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intradermal use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
0.1 mL, two injections on deltoid area of both the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 4: Short PVRV IM PrEP regimen | ||||||||||||||||||||||||||||||
Arm description |
Subjects received a single IM dose of purified Vero cell rabies vaccine (PVRV) on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Purified Vero cell Rabies Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Verorab®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, single IM injection on the deltoid area of the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 5: Short PVRV ID PrEP regimen | ||||||||||||||||||||||||||||||
Arm description |
Subjects received two ID doses of PVRV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Purified Vero cell Rabies Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Verorab®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intradermal use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
0.1 mL, two ID injections on deltoid area of both the arms.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||||||||
Period 2 title |
PEP Vaccination Phase: up to 5.8 Months
|
||||||||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||||
Arm title
|
Group 1: Short HDCV IM Post-exposure Prophylaxis (PEP) Regimen | ||||||||||||||||||||||||||||||
Arm description |
Pre-immunised subjects received a single IM dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Human Diploid Cell Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Imovax® Rabies
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
1 mL, single IM injection on the deltoid area of the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 2: Reference HDCV IM PEP Regimen | ||||||||||||||||||||||||||||||
Arm description |
Pre-immunised subjects received a single IM dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Human Diploid Cell Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Imovax® Rabies
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
1 mL, single IM injection on the deltoid area of the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 3: Short HDCV ID PEP regimen | ||||||||||||||||||||||||||||||
Arm description |
Pre-immunised subjects received a single ID dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Human Diploid Cell Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Imovax® Rabies
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intradermal use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
0.1 mL, single ID injection on deltoid area of both the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 4: Short PVRV IM PEP regimen | ||||||||||||||||||||||||||||||
Arm description |
Pre-immunised subjects received a single IM dose of PVRV on Year 1 and on Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Purified Vero cell Rabies Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Verorab®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, single IM injection on the deltoid area of the arm.
|
||||||||||||||||||||||||||||||
Arm title
|
Group 5: Short PVRV ID PEP regimen | ||||||||||||||||||||||||||||||
Arm description |
Pre-immunised subjects received a single ID dose of PVRV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||||
Investigational medicinal product name |
Purified Vero cell Rabies Vaccine
|
||||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||||
Other name |
Verorab®
|
||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
||||||||||||||||||||||||||||||
Routes of administration |
Intradermal use
|
||||||||||||||||||||||||||||||
Dosage and administration details |
0.1 mL, single ID injection on deltoid area of both the arms.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Notes [1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period. Justification: Post PrEP phase, only pre-immunised subjects were vaccinated with a simulated PEP regimen. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 1: Short HDCV IM PrEP Regimen
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single IM dose of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 2: Reference HDCV IM PrEP Regimen
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single IM dose of HDCV on Day 0, Day 7, and Day 21 and were followed up to 1 year post last PrEP vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 3: Short HDCV Intradermal (ID) PrEP regimen
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received two ID doses of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 4: Short PVRV IM PrEP regimen
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received a single IM dose of purified Vero cell rabies vaccine (PVRV) on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 5: Short PVRV ID PrEP regimen
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received two ID doses of PVRV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group 1: Short HDCV IM PrEP Regimen
|
||
Reporting group description |
Subjects received a single IM dose of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||
Reporting group title |
Group 2: Reference HDCV IM PrEP Regimen
|
||
Reporting group description |
Subjects received a single IM dose of HDCV on Day 0, Day 7, and Day 21 and were followed up to 1 year post last PrEP vaccination. | ||
Reporting group title |
Group 3: Short HDCV Intradermal (ID) PrEP regimen
|
||
Reporting group description |
Subjects received two ID doses of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||
Reporting group title |
Group 4: Short PVRV IM PrEP regimen
|
||
Reporting group description |
Subjects received a single IM dose of purified Vero cell rabies vaccine (PVRV) on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||
Reporting group title |
Group 5: Short PVRV ID PrEP regimen
|
||
Reporting group description |
Subjects received two ID doses of PVRV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. | ||
Reporting group title |
Group 1: Short HDCV IM Post-exposure Prophylaxis (PEP) Regimen
|
||
Reporting group description |
Pre-immunised subjects received a single IM dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||
Reporting group title |
Group 2: Reference HDCV IM PEP Regimen
|
||
Reporting group description |
Pre-immunised subjects received a single IM dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||
Reporting group title |
Group 3: Short HDCV ID PEP regimen
|
||
Reporting group description |
Pre-immunised subjects received a single ID dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||
Reporting group title |
Group 4: Short PVRV IM PEP regimen
|
||
Reporting group description |
Pre-immunised subjects received a single IM dose of PVRV on Year 1 and on Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||
Reporting group title |
Group 5: Short PVRV ID PEP regimen
|
||
Reporting group description |
Pre-immunised subjects received a single ID dose of PVRV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. |
|
|||||||||||||
End point title |
Percentage of Subjects With Rabies Virus Neutralising Antibodies (RVNA) Titer Greater Than or Equal to (>=) 0.5 International Units Per Millilitre (IU/mL) After Last PrEP Vaccination with HDCV: Group 1 and Group 2 [1] | ||||||||||||
End point description |
RVNA titer was assessed using the rapid fluorescent focus inhibition test (RFFIT) assay method. Analysis was performed on the PrEP Per-Protocol Analysis Set (PPAS) that included all randomised subjects who received at least one dose of the study vaccines during the PrEP period and had no relevant protocol deviations.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
14 days after last PrEP vaccination (i.e. Day 21 for Group 1; Day 35 for Group 2)
|
||||||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Data for this endpoint was not planned to be collected and analysed for Group 3, 4 and 5, as pre-specified in protocol. |
|||||||||||||
|
|||||||||||||
Statistical analysis title |
Group 1 versus Group 2 | ||||||||||||
Comparison groups |
Group 1: Short HDCV IM PrEP Regimen v Group 2: Reference HDCV IM PrEP Regimen
|
||||||||||||
Number of subjects included in analysis |
318
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
non-inferiority [2] | ||||||||||||
Method |
|||||||||||||
Parameter type |
Difference in percentage | ||||||||||||
Point estimate |
-3.349
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
-6.751 | ||||||||||||
upper limit |
0.464 | ||||||||||||
Notes [2] - Non-inferiority was demonstrated if the lower limit of the 95% confidence interval of the difference of the 2 percentages (Group1-Group2) was greater than (>) -5%. |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects With RVNA Titer >= 0.5 IU/mL at Day 0 (pre-vaccination) and 14 Days After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. Analysis was performed on the PrEP Full Analysis Set (FAS) that included all randomised subjects who received at least 1 dose of the study vaccines during the PrEP period. Here, ‘n’= subjects with available data for each specified category. Here, '99999' was used as space fillers and signifies that the subjects of the respective groups did not receive any vaccination at the specified time-point and therefore were not evaluable.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 14 days after last PrEP vaccination (i.e. Day 21 for Groups 1, 3, 4 and 5; Day 35 for Group 2)
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects With RVNA Titer >= 0.2 IU/mL at Day 0 (pre-vaccination) and 14 Days After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category. Here, '99999' was used as space fillers and signifies that the subjects of the respective groups did not receive any vaccination at the specified time-point and therefore were not evaluable.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 14 days after last PrEP vaccination (i.e. Day 21 for Groups 1, 3, 4 and 5; Day 35 for Group 2)
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titers (GMTs) of RVNA at Day 0 (pre-vaccination) and 14 Days After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||
End point description |
RVNA titers was assessed using the RFFIT assay method and expressed in terms of IU/mL. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category. Here, '99999' was used as space fillers and signifies that the subjects of the respective groups did not receive any vaccination at the specified time-point and therefore were not evaluable.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 14 days after last PrEP vaccination (i.e. Day 21 for Groups 1, 3, 4 and 5; Day 35 for Group 2)
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titer Ratio (GMTR) of RVNA Following PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs of 14 days after last PrEP vaccination and GMTs of pre-vaccination. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category. Here, '99999' was used as space fillers and signifies that the subjects of the respective groups did not receive any vaccination at the specified time-point and therefore were not evaluable.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
Day 0 (pre-vaccination) and 14 days after last PrEP vaccination (i.e. Day 21 for Groups 1, 3, 4 and 5; Day 35 for Group 2)
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects With RVNA Titer >= 0.5 IU/mL at 6 Months and 1 Year After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
6 months (i.e. Day 180) and 1 year (i.e. Year 1) after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects With RVNA Titer >= 0.2 IU/mL at 6 Months and 1 Year After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
6 months (i.e. Day 180) and 1 year (i.e. Year 1) after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titers of RVNA at 6 Months and 1 Year After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method and expressed in terms of IU/mL. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
6 months (i.e. Day 180) and 1 year (i.e. Year 1) after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titer Ratio (GMTR) of RVNA at 6 Months After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs of 6 months after last PrEP vaccination and GMTs of 14 days after last PrEP vaccination. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category. Here, '99999' was used as space fillers and signifies that the subjects of the respective groups did not receive any vaccination at the specified time-point and therefore were not evaluable.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
14 days (i.e. Day 21 for Groups 1, 3, 4 and 5; Day 35 for Group 2) and 6 months (i.e. Day 180) after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titer Ratio (GMTR) of RVNA at 1 Year After Last PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs of 1 year after last PrEP vaccination and GMTs of 14 days after last PrEP vaccination. Analysis was performed on the PrEP FAS population. Here, ‘n’= subjects with available data for each specified category. Here, '99999' was used as space fillers and signifies that the subjects of the respective groups did not receive any vaccination at the specified time-point and therefore were not evaluable.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
14 days (i.e. Day 21 for Groups 1, 3, 4 and 5; Day 35 for Group 2) and 1 year (i.e. Year 1) after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects With RVNA Titer >=0.5 IU/mL at 7 Days and 14 Days After First Simulated PEP Vaccination With HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. Analysis was performed on the PEP FAS population that included subjects who received at least 1 dose of the study vaccines during the simulated PEP period. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days (i.e. Year 1 + 7 days) and 14 days (i.e. Year 1 + 14 days) after first simulated PEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Percentage of Subjects With RVNA Titer >=0.2 IU/mL at 7 Days and 14 Days After First Simulated PEP Vaccination With HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. Analysis was performed on the PEP FAS population. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days (i.e. Year 1 + 7 days) and 14 days (i.e. Year 1 + 14 days) after first simulated PEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titers of RVNA at 7 Days and 14 Days After First Simulated PEP Vaccination With HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method and expressed in terms of IU/mL. Analysis was performed on the PEP FAS population. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days (i.e. Year 1 + 7 days) and 14 days (i.e. Year 1 + 14 days) after first simulated PEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titer Ratio (GMTR) of RVNA After First Simulated PEP vaccination With HDCV or PVRV | ||||||||||||||||||||||||||||||||||||
End point description |
RVNA titer was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs of 7 and 14 days after first simulated PEP vaccination and GMTs of 1 year after the last PrEP vaccination. Analysis was performed on the PEP FAS population. Here, ‘n’= subjects with available data for each specified category.
|
||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||
End point timeframe |
7 days (i.e. Year 1 + 7 days) and 14 days (i.e. Year 1 + 14 days) after first simulated PEP vaccination and 1 Year after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects With Immediate Unsolicited Systemic Adverse Events (AEs) Following PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||
End point description |
An AE was any untoward medical occurrence in a subject who received study vaccines and did not necessarily had to have causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions. All subjects were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited systemic AEs in the eCRF. Analysis was performed on the PrEP safety analysis set (SafAS) population that included subjects who had received at least 1 dose of the study vaccine during the PrEP period and were analysed according to the actual vaccine they received.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Within 30 minutes after any PrEP vaccination
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects With Immediate Unsolicited Systemic Adverse Events Following PEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||
End point description |
An AE was any untoward medical occurrence in a subject who received study vaccines and did not necessarily had to have causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the eCRF in terms of diagnosis and/or onset post-vaccination. Systemic AEs were all AEs that were not injection or administration site reactions. All subjects were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited systemic AEs in the eCRF. Analysis was performed on the simulated PEP SafAS population that include subjects who had received at least 1 dose of the study vaccine during the simulated PEP period and were analysed according to the actual vaccine they received.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Within 30 minutes after any simulated PEP vaccination
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Solicited Injection Site Reactions Following PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
A solicited reaction (SR) was an adverse reaction (AR) observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema and swelling. Analysis was performed on the PrEP SafAS population. Here, ‘n’= subjects with available data for each specified category and '99999' was used as space fillers and signifies that the subjects of Groups 1, 3, 4 and 5 did not receive any vaccination at Day 21 and therefore were not evaluable. Here, "vacc" in the categories below denotes "vaccination".
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 7 days after any and each PrEP vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Solicited Systemic Reactions Following PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
A SR was an AR observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise and myalgia. Analysis was performed on the PrEP SafAS population. Here, ‘n’= subjects with available data for each specified category and '99999' was used as space fillers and signifies that the subjects of Groups 1, 3, 4 and 5 did not receive any vaccination at Day 21 and therefore were not evaluable. Here, "vacc" in the categories below denotes "vaccination".
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 7 days after any and each PrEP vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Unsolicited Non-Serious Adverse Events Following PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
An AE was any untoward medical occurrence in a subject who received study vaccines and did not necessarily had to have causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the eCRF in terms of diagnosis and/or onset post-vaccination. Analysis was performed on the PrEP SafAS population. Here, ‘n’= subjects with available data for each specified category and '99999' was used as space fillers and signifies that the subjects of Groups 1, 3, 4 and 5 did not receive any vaccination at Day 21 and therefore were not evaluable. Here, "vacc" in the categories below denotes "vaccination".
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 28 days after any and each PrEP vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects With Serious Adverse Events (SAEs) Following PrEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||
End point description |
An SAE was any untoward medical occurrence that at any dose resulted in death; life-threatening; initial or prolonged inpatient hospitalisation; persistent or significant disability/incapacity; congenital anomaly/birth defect or a medically important event. Analysis was performed on the PrEP SafAS population.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
From Day 0 (pre-vaccination) up to 28 days after last PrEP vaccination
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Solicited Injection Site Reactions Following PEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
A SR was an AR observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reactions included pain, erythema and swelling. Analysis was performed on the PEP SafAS population. Here, ‘n’= subjects with available data for each specified category. Here, "vacc" in the categories below denotes "vaccination" and “D” denotes “Days”.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 7 days after any and each simulated PEP vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Solicited Systemic Reactions Following PEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
A SR was an AR observed and reported under the conditions (symptom and onset) pre-listed (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise and myalgia. Analysis was performed on the PEP SafAS population. Here, ‘n’= subjects with available data for each specified category. Here, "vacc" in the categories below denotes "vaccination" and "D" denotes "Days".
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 7 days after any and each simulated PEP Vaccination
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Unsolicited Non-Serious Adverse Events Following Simulated PEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||||||||||||||||||||
End point description |
An AE was any untoward medical occurrence in a subject who received study vaccines and did not necessarily had to have causal relationship with treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the eCRF in terms of diagnosis and/or onset post-vaccination. Analysis was performed on the PEP SafAS population. Here, ‘n’= subjects with available data for each specified category. Here, "vacc" in the categories below denotes "vaccination".
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Up to 28 days after any and each simulated PEP vaccination
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Subjects With Serious Adverse Events Following PEP Vaccination with HDCV or PVRV | ||||||||||||||||||||||||
End point description |
An SAE was any untoward medical occurrence that at any dose resulted in death; life-threatening; initial or prolonged inpatient hospitalisation; persistent or significant disability/incapacity; congenital anomaly/birth defect or a medically important event. Analysis was performed on the PEP SafAS population.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
From 1 year after last PrEP vaccination up to 31 days after last simulated PEP vaccination
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Related SAEs, Unrelated Deaths, and Life-threatening SAEs at Time Period Between PrEP and PEP Phase | ||||||||||||||||||||||||||||||||||||||||||
End point description |
An SAE was any untoward medical occurrence that at any dose resulted in death; life-threatening; initial or prolonged inpatient hospitalisation; persistent or significant disability/incapacity; congenital anomaly/birth defect or a medically important event. All related SAEs, unrelated deaths, and life-threatening SAEs were collected between the end of the PrEP phase and the beginning of the PEP phase. Analysis was performed on PrEP SafAS population.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From 28 days after last PrEP vaccination up to 1 year after last PrEP vaccination
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Female Subjects Who Were Pregnant During PrEP Phase | ||||||||||||||||||||||||
End point description |
Number of female subjects who got pregnant during PrEP phase was collected and reported. Analysis was performed on PrEP SafAS population. Number of subjects analysed = female subjects evaluable for this endpoint.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
From Day 0 (pre-vaccination) up to 28 days after last PrEP vaccination
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Number of Female Subjects Who Were Pregnant Between PrEP and PEP Phase | ||||||||||||||||||||||||
End point description |
Number of female subjects who got pregnant between the end of the PrEP phase and the beginning of the PEP phase was collected and reported in this endpoint. Analysis was performed on PrEP SafAS population. Number of subjects analysed = female subjects evaluable for this endpoint.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
From 28 days after last PrEP vaccination up to 1 year after last PrEP vaccination
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
AE data: from Day 0 (pre-vaccination) up to 28 days post any vaccination. SR data: collected within 7 days post any vaccination. SAE data: collected throughout study (i.e. up to 28 and 31 days after last PrEP and simulated PEP vaccination, respectively).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
A SR was an AE that was pre-listed (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination. Analysis was performed on SafAS population.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 1: Short HDCV IM PrEP + PEP Regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In PrEP regimen, subjects received a single IM dose of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. In simulated PEP regimen, pre-immunised subjects received a single dose of HDCV at Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 2: Reference HDCV IM PrEP + PEP Regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In PrEP regimen, subjects received a single IM dose of HDCV on Day 0, Day 7, and Day 21 and were followed up to 1 year post last PrEP vaccination. In simulated PEP regimen, pre-immunised subjects received a single dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 3: Short HDCV ID PrEP + PEP regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In PrEP regimen, subjects received two ID doses of HDCV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. In simulated PEP regimen, pre-immunised subjects received a single dose of HDCV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 4: Short PVRV IM PrEP + PEP regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In PrEP regimen, subjects received a single IM dose of purified Vero cell rabies vaccine (PVRV) on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. In simulated PEP regimen, pre-immunised subjects received a single dose of PVRV on Year 1 and on Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 5: Short PVRV ID PrEP + PEP regimen
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In PrEP regimen, subjects received two ID doses of PVRV on Day 0 and Day 7 and were followed up to 1 year post last PrEP vaccination. In simulated PEP regimen, Pre-immunised subjects received a single dose of PVRV on Year 1 and Year 1 + 3 days, post last PrEP vaccination and were followed up for 31 days post last PEP vaccination. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |